Immunitybio Inc
IBRX
NASDAQ
Biotechnology
$7.57
USD
-0.08 (-1.05%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.11B
Volume 4.9M
Revenue
$165.79M
TTM
+192.9%
YoY
Gross Margin
99%
TTM
-0.3%
YoY
Net Income
$-992.42M
TTM
-170.3%
YoY
Operating Cash Flow
$-281.14M
TTM
+19.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 26.4 | 32.1 | 38.3 | 44.2 | 51.2 |
YoY Growth | +2423.9% | +425.1% | +407.0% | +167.6% | +93.9% |
Cost of Revenue | 0.1 | 0.2 | 0.4 | 0.2 | 0.3 |
Gross Profit | 26.3 | 31.9 | 37.9 | 44.0 | 50.9 |
Selling, General & Administrative | 42.3 | 36.3 | 38.7 | 45.8 | 51.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 97.6 | 87.5 | 102.6 | 113.8 | 112.6 |
Operating Income | -71.3 | -55.6 | -64.7 | -69.8 | -61.7 |
EBITDA | -67.4 | -51.7 | -60.8 | -65.4 | -57.3 |
Other Income / Expense | 7.9 | 13.8 | 27.5 | -534.5 | -137.4 |
Total Other Income / Expense | -21.0 | -11.7 | 2.6 | -563.0 | -168.7 |
Income Before Income Taxes | -92.3 | -67.3 | -62.1 | -632.8 | -230.4 |
Income Taxes | 0.3 | -0.0 | -0.1 | 0.0 | 0.0 |
Net Income | -92.6 | -67.3 | -62.0 | -632.8 | -230.4 |
Consolidated Net Income / Loss | -92.6 | -67.3 | -62.0 | -632.8 | -230.4 |
Net Income Attributable to Common Shareholders | -92.6 | -67.3 | -61.9 | -632.8 | -230.4 |
Basic EPS | -$0.10 | -$0.07 | -$0.06 | -$0.62 | -$0.22 |
Diluted EPS | -$0.10 | -$0.07 | -$0.06 | -$0.62 | -$0.22 |
Basic Shares Outstanding | 888.2M | 946.6M | 991.5M | 1,026.9M | 1,050.1M |
Diluted Shares Outstanding | 888.2M | 946.6M | 991.5M | 1,026.9M | 1,050.1M |